Logo image of RKDA

ARCADIA BIOSCIENCES INC (RKDA) Stock Fundamental Analysis

NASDAQ:RKDA - Nasdaq - US0390143032 - Common Stock - Currency: USD

3.59  0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RKDA. RKDA was compared to 89 industry peers in the Food Products industry. While RKDA has a great health rating, there are worries on its profitability. RKDA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RKDA had negative earnings in the past year.
In the past year RKDA has reported a negative cash flow from operations.
RKDA had negative earnings in each of the past 5 years.
RKDA had a negative operating cash flow in each of the past 5 years.
RKDA Yearly Net Income VS EBIT VS OCF VS FCFRKDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

RKDA has a Return On Assets of -52.07%. This is amonst the worse of the industry: RKDA underperforms 87.64% of its industry peers.
With a Return On Equity value of -113.10%, RKDA is not doing good in the industry: 82.02% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -52.07%
ROE -113.1%
ROIC N/A
ROA(3y)-58.73%
ROA(5y)-43.88%
ROE(3y)-98.37%
ROE(5y)-71.81%
ROIC(3y)N/A
ROIC(5y)N/A
RKDA Yearly ROA, ROE, ROICRKDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

RKDA has a Gross Margin of 44.33%. This is amongst the best in the industry. RKDA outperforms 96.63% of its industry peers.
RKDA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RKDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.63%
GM growth 5Y13.12%
RKDA Yearly Profit, Operating, Gross MarginsRKDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

7

2. Health

2.1 Basic Checks

RKDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RKDA has more shares outstanding than it did 1 year ago.
RKDA has more shares outstanding than it did 5 years ago.
RKDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RKDA Yearly Shares OutstandingRKDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
RKDA Yearly Total Debt VS Total AssetsRKDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RKDA has an Altman-Z score of -29.33. This is a bad value and indicates that RKDA is not financially healthy and even has some risk of bankruptcy.
RKDA has a Altman-Z score of -29.33. This is amonst the worse of the industry: RKDA underperforms 92.13% of its industry peers.
There is no outstanding debt for RKDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.33
ROIC/WACCN/A
WACC8.83%
RKDA Yearly LT Debt VS Equity VS FCFRKDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.61 indicates that RKDA has no problem at all paying its short term obligations.
The Current ratio of RKDA (3.61) is better than 88.76% of its industry peers.
RKDA has a Quick Ratio of 3.25. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.25, RKDA belongs to the top of the industry, outperforming 94.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.25
RKDA Yearly Current Assets VS Current LiabilitesRKDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

RKDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.41%, which is quite impressive.
The Revenue has decreased by -5.33% in the past year.
RKDA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.95% yearly.
EPS 1Y (TTM)70.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.65%
Revenue 1Y (TTM)-5.33%
Revenue growth 3Y-9.38%
Revenue growth 5Y33.95%
Sales Q2Q%3.93%

3.2 Future

RKDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.22% yearly.
The Revenue is expected to grow by 25.70% on average over the next years. This is a very strong growth
EPS Next Y44.36%
EPS Next 2Y25.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year30%
Revenue Next 2Y25.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RKDA Yearly Revenue VS EstimatesRKDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
RKDA Yearly EPS VS EstimatesRKDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RKDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RKDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RKDA Price Earnings VS Forward Price EarningsRKDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RKDA Per share dataRKDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

RKDA's earnings are expected to grow with 25.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.22%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RKDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCADIA BIOSCIENCES INC

NASDAQ:RKDA (5/2/2025, 2:59:37 PM)

3.59

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners10.76%
Inst Owner Change-0.01%
Ins Owners0.46%
Ins Owner Change0.01%
Market Cap4.92M
Analysts82.86
Price Target12.24 (240.95%)
Short Float %0.97%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-136.09%
Min EPS beat(2)-229.37%
Max EPS beat(2)-42.82%
EPS beat(4)1
Avg EPS beat(4)-75.41%
Min EPS beat(4)-229.37%
Max EPS beat(4)21.21%
EPS beat(8)4
Avg EPS beat(8)-31.38%
EPS beat(12)8
Avg EPS beat(12)-10.06%
EPS beat(16)12
Avg EPS beat(16)6.42%
Revenue beat(2)1
Avg Revenue beat(2)3.53%
Min Revenue beat(2)-0.65%
Max Revenue beat(2)7.71%
Revenue beat(4)3
Avg Revenue beat(4)12.15%
Min Revenue beat(4)-0.65%
Max Revenue beat(4)38.42%
Revenue beat(8)5
Avg Revenue beat(8)-0.47%
Revenue beat(12)6
Avg Revenue beat(12)-4.19%
Revenue beat(16)7
Avg Revenue beat(16)-6.37%
PT rev (1m)0%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-108.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.97
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-5.17
EYN/A
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)-7.04
FCFYN/A
OCF(TTM)-7.03
OCFYN/A
SpS3.68
BVpS4.54
TBVpS4.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.07%
ROE -113.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.33%
FCFM N/A
ROA(3y)-58.73%
ROA(5y)-43.88%
ROE(3y)-98.37%
ROE(5y)-71.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.63%
GM growth 5Y13.12%
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.16%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.25
Altman-Z -29.33
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)10.16%
Cap/Depr(5y)96.24%
Cap/Sales(3y)0.38%
Cap/Sales(5y)9.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.65%
EPS Next Y44.36%
EPS Next 2Y25.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.33%
Revenue growth 3Y-9.38%
Revenue growth 5Y33.95%
Sales Q2Q%3.93%
Revenue Next Year30%
Revenue Next 2Y25.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y44.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-50.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.05%
OCF growth 3YN/A
OCF growth 5YN/A